The primary goal of healthcare providers and pharmaceutical companies is to improve patient outcomes. Accurate patient flow forecasting is critical in achieving this objective.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
